Health Trials

VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT

ConditionsOlder PatientsMyeloid MalignanciesConditioningHematopoietic Stem Cell Transplantation (HSCT)
Trial statusNot yet recruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age60-75
SponsorNanfang Hospital, Southern Medical University

About this trial

The purpose of this study is to compare the efficacy and safety of venetoclax+decitabine+busulfan+fludarabine (VEN+DAC+Bu2Flu4) regimen with busulfan+fludarabine (Bu2Flu5) regimen in older patients with myeloid malignancies undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Eligibility criteria

Qualifiers

60-75 years

Acute myeloid leukaemia in first complete remission or myelodysplastic syndrome

Willing to undergo the first allo-HSCT

Eastern Cooperative Oncology Group performance status of 0-2

Disqualifiers

Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)

Patients with any conditions not suitable for the trial (investigators' decision)

Trial design

Treatments tested in this trial

  • Venetoclax (VEN)
  • Decitabine (DAC)
  • Busulfan (Bu)
  • Fludarabine (Flu)
  • Fludarabine (Flu)

Treatment groups

160 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Nanfang Hospital, Southern Medical University

Lead sponsor

Source ClinicalTrials.gov